Fecal Transplant Therapy Market Explained: What Is Fueling Growth To $2.87 Billion By 2030?

Fecal Transplant Therapy Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Fecal Transplant Therapy Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The fecal transplant therapy market size has experienced significant growth in recent years. This market is anticipated to expand from $2.15 billion in 2025 to $2.28 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.2%. The historical growth can be attributed to its documented effectiveness in treating recurrent CDI, increasing hospital awareness of microbiome therapies, the expansion of gastroenterology specialty services, the availability of basic stool preparation technologies, and early-stage clinical trials.

The fecal transplant therapy market is projected to experience substantial growth in the coming years. It is anticipated to reach $2.87 billion by 2030, with a compound annual growth rate (CAGR) of 5.9%. This market expansion during the forecast period is driven by an increasing diversification of disease indications, a rising demand for regulated and standardized products, the expansion of outpatient fmt procedures, growing investment in microbiome therapeutics, and advancements in automated stool processing systems. Key trends expected in the forecast period include an increasing clinical adoption of stool-based therapies, a rising development of capsule and suspension formats, a growing exploration of neurological and metabolic indications, the expansion of in-hospital fmt programs, and an enhanced emphasis on safety and standardization.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=98127453&type=smp&name=Fecal%20Transplant%20Therapy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Fecal Transplant Therapy Market Growth Catalysts And Demand Drivers

The growing incidence of inflammatory bowel disease is anticipated to propel the future expansion of fecal transplant therapy markets. Inflammatory bowel disease (IBD) is defined as persistent inflammation of the gastrointestinal tract, encompassing conditions such as Crohn’s disease and ulcerative colitis. The rise in IBD cases stems from factors including increased consumption of highly processed foods, frequent or inappropriate use of antibiotics, enhanced hygiene, and reduced exposure to infectious agents during childhood. Fecal transplant therapy aims to restore a balanced gut microbiota, which assists in mitigating inflammation and improving symptoms for individuals with inflammatory bowel disease, potentially impacting its management and progression. For instance, in June 2023, according to Crohn’s and Colitis Canada, a Canada-based non-profit organization, 470,000 inflammatory bowel disease (IBD) sufferers are projected in Canada by 2035, an increase from an estimated 322,600 in 2023. Consequently, the increasing prevalence of inflammatory bowel disease is driving the growth of the fecal transplant therapy market.

Fecal Transplant Therapy Market Segmentation: How Does The Market Break Down By Category?

The fecal transplant therapy market covered in this report is segmented –

1) By Procedure: Fecal Enema, Fecal Bacteriotherapy, Stool Transplant, Human Probiotic Infusion, Fecal Transfusion

2) By Disease: Clostridium Difficile Infection, Autism, Obesity, Parkinson’s Disease (PD), Diabetes Mellitus, Other Diseases

3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Fecal Enema: Retention Enema, Cleansing Enema, Retention-Based Fecal Transplants, Home Administration Kits

2) By Fecal Bacteriotherapy: Suspension-Based Bacteriotherapy, Capsule Formulations, Customized Bacterial Preparations, Single Strain vs. Multi-Strain Products

3) By Stool Transplant: Direct Stool Transplant Procedures, Stool Suspension Transplant, Stool Capsule Transplant, Automated Stool Preparation Systems

4) By Human Probiotic Infusion: Single-Strain Probiotic Infusions, Multi-Strain Probiotic Infusions, Probiotic Blends With Prebiotics, Infusion Kits for Healthcare Providers

5) By Fecal Transfusion: Intravenous Fecal Transfusion, Transfusion via Gastrostomy Tube, Pre-Packaged Fecal Transfusion Solutions, Fecal Transfusion For Research Purposes

Fecal Transplant Therapy Market Industry Trends: What’s Reshaping Demand?

Key players within the fecal transplant therapy market are concentrating on creating novel treatments, including oral pill versions of fecal microbiota transplantation (FMT) therapy, aiming to boost patient adherence and expand the availability of the therapy. This oral form of fecal microbiota transplantation (FMT) therapy comprises live bacteria from donor feces, enclosed in capsules for ingestion, whose purpose is to restore beneficial gut bacteria and enhance overall intestinal well-being. For example, in April 2023, Seres Therapeutics Inc., a US-based biotechnology company, along with Nestlé Health Science S.A., a Switzerland-based healthcare company, introduced VOWST. Delivered in capsule form, VOWST offers a convenient and less intrusive treatment alternative for preventing recurrent clostridioides difficile infection (rCDI) in adults after receiving antibacterial therapy. In contrast to conventional fecal microbiota transplantation (FMT), which entails the transfer of entire stools, VOWST employs live bacterial spores from various Firmicute species sourced from the fecal microbiota of healthy human donors, believed to re-establish the gut microbiome.

Fecal Transplant Therapy Market Competitive Overview And Top Companies

Major companies operating in the fecal transplant therapy market are Mayo Clinic, Mount Sinai Health System Inc., Northwestern Medicine, NYU Langone Health, Michigan Medicine, UCLA Health, Duke University Health System Inc., Stanford Health Care, Ferring Pharmaceuticals, Cincinnati Children’s Hospital Medical Center, Emory Healthcare, Cambridge University Hospitals NHS Foundation Trust, Hamilton Health Sciences Corporation, Brigham and Women’s Faulkner Hospital Inc., Rebiotix Inc., Seres Therapeutics Inc., UPMC Hillman Cancer Center, OpenBiome, Center for Digestive Disease, BiomeBank Incorporated, The Regents of the University of California

View The Full Fecal Transplant Therapy Market Report:

https://thebusinessresearchcompany.com/report/fecal-transplant-therapy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Fecal Transplant Therapy Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the fecal transplant therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fecal transplant therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model